Drug profile · INN
asparaginase
GRASPA
asparaginase (GRASPA) is a asparagine hydrolytic enzyme. Current US regulatory status: approved.
Drug details — asparaginase
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 7
- Programs
- 8
- Data quality
- 0.83
Quick answer
asparaginase (GRASPA) is a asparagine hydrolytic enzyme. Current US regulatory status: approved.
Key facts
Mechanism of action
Asparagine hydrolytic enzyme
Primary target: Asparagine
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12121571
Recombinant L-asparaginase
granted -
US 11802279
Modified L-asparaginase
granted -
US 11578315
Truncated guinea pig L-asparaginase variants and methods of use
granted -
US 11046946
PEGylated L-asparaginase
granted -
US 10174302
Modified L-asparaginase
granted -
US 9920311
PEGylated L-asparaginase
granted -
WO 2007147454
SYNTHÈSE CHIMIQUE DE LA CU-64ASP (CUIVRE-64ASPARAGINASE ; [64CU]ASPARARAGINASE) POUR PET SCAN ET RADIOTHÉRAPIE
granted
Frequently asked questions
What is asparaginase?
asparaginase (GRASPA) is a asparagine hydrolytic enzyme. Current US regulatory status: approved.
What is the brand name for asparaginase?
GRASPA is a marketed brand name for asparaginase. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of asparaginase?
asparaginase has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.